Therapy Detail

Therapy Name Nab-paclitaxel + Gemcitabine
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Gemcitabine Gemzar Difluorodeoxycytidine Hydrochlorothiazide Chemotherapy - Antimetabolite 10 Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).
nab-paclitaxel Abraxane ABI-007 Chemotherapy - Taxane 2 Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01621243 Phase Ib/II Nab-paclitaxel + Gemcitabine Necuparanib M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer Terminated
NCT02077881 Phase Ib/II indoximod Nab-paclitaxel + Gemcitabine Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT03336216 Phase II Cabiralizumab + Gemcitabine + Nab-Paclitaxel + Nivolumab Cabiralizumab + Nivolumab FOLFIRI Nab-paclitaxel + Gemcitabine Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer Recruiting
NCT02574663 Phase I Nab-paclitaxel + Gemcitabine Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Active, not recruiting
NCT02993731 Phase III Gemcitabine + nab-paclitaxel + Napabucasin Nab-paclitaxel + Gemcitabine A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) Recruiting
NCT02101021 Phase II Nab-paclitaxel + Gemcitabine Momelotinib Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated
NCT01803282 Phase I GS-5745 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed FOLFIRI Nab-paclitaxel + Gemcitabine Paclitaxel + Carboplatin Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Active, not recruiting
NCT01921751 Phase II Nab-paclitaxel + Gemcitabine Capecitabine High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Terminated
NCT02109445 Phase II Nab-paclitaxel + Gemcitabine PF-03084014 Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies Terminated
NCT03086369 Phase Ib/II Olaratumab + nab-paclitaxel + Gemcitabine Nab-paclitaxel + Gemcitabine A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Recruiting
NCT03563144 Phase II Gemcitabine Nab-paclitaxel + Gemcitabine NANT pancreatic cancer vaccine combination QUILT-3.088: NANT Pancreatic Cancer Vaccine Not yet recruiting
NCT02570711 Phase II Acalabrutinib Nab-paclitaxel + Gemcitabine Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer Terminated
NCT02436668 Phase II Nab-paclitaxel + Gemcitabine Ibrutinib Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting
NCT02340117 Phase II SGT-53 Nab-paclitaxel + Gemcitabine Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer Recruiting
NCT03496662 Phase Ib/II Nivolumab BMS-813160 + Gemcitabine + nab-paclitaxel Nab-paclitaxel + Gemcitabine BMS-813160 + Gemcitabine + nab-paclitaxel + Nivolumab BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
NCT01488552 Phase Ib/II Oxaliplatin FOLFIRI Nab-paclitaxel + Gemcitabine Metformin Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Completed
NCT01804530 Phase I PLX7486 Nab-paclitaxel + Gemcitabine Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated
NCT02879318 Phase II Nab-paclitaxel + Gemcitabine Durvalumab + Tremelimumab Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma Active, not recruiting